Mga Batayang Estadistika
| CIK | 1907108 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lexeo Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilo |
|
| August 14, 2025 |
Exhibit 10.3 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Weill Cornell Medicine Enterprise Innovation Center for Technology Licensing 1155 York Avenue New York, NY 10065 P: 646.962.7045 innovation.weill.cornell.edu May 21, 202 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 14, 2025 |
PART I-FINANCIAL INFORMATION PART II-OTHER INFORMATION SIGNATURES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41855 Lexeo Therapeutics, Inc. |
|
| July 1, 2025 |
41,630,514 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-288025 PROSPECTUS 41,630,514 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 41,630,514 shares, or the Shares, of common stock of Lexeo Therapeutics, Inc., a Delaware corporation, or the Company, par value $0.0001 per share, or the Common Stock, by the selling stockholders iden |
|
| June 30, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 26, 2025 |
As filed with the Securities and Exchange Commission on June 26, 2025 Table of Contents As filed with the Securities and Exchange Commission on June 26, 2025 Registration No. |
|
| June 13, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) Lexeo Therapeutics, Inc. |
|
| June 13, 2025 |
As filed with the Securities and Exchange Commission on June 13, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 13, 2025 Registration No. |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e) |
|
| May 27, 2025 |
Exhibit 4.1 THIS PRE-FUNDED WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS PRE-FUNDED WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUC |
|
| May 27, 2025 |
Exhibit 99.1 Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with parti |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 27, 2025 |
Form of Securities Purchase Agreement, dated May 27, 2025 Exhibit 10.1 securities PURCHASE AGREEMENT BY AND AMONG LEXEO THERAPEUTICS, INC. AND THE PURCHASERS May 27, 2025 1 TABLE OF CONTENTS 1. Definitions 5 2. Purchase and Sale of Securities 8 2.1 Purchase and Sale 8 2.2 Closing 8 3. Representations and Warranties of the Company 9 3.1 Financial Statements 9 3.2 No Material Adverse Change 9 3.3 Organization and Good Standing 9 3.4 Capitalization 10 3.5 S |
|
| May 27, 2025 |
Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN |
|
| May 27, 2025 |
Form of Registration Rights Agreement, dated May 27, 2025 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of May 27, 2025 by and among Lexeo Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Company and the Purc |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2025 |
Exhibit 99.1 Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enro |
|
| May 12, 2025 |
PART I-FINANCIAL INFORMATION PART II-OTHER INFORMATION SIGNATURES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41855 Lexeo Therapeutics, Inc. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| April 7, 2025 |
Exhibit 99.2 Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac biomarkers and functi |
|
| April 7, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 07, 2025 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 7, 2025 |
Interim Data Update of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy April 7, 2025 Exhibit 99. |
|
| March 24, 2025 |
Insider Trading and Window Period Policy Exhibit 19.1 LEXEO THERAPEUTICS, INC. INSIDER TRADING AND WINDOW PERIOD POLICY I. Introduction This policy determines acceptable transactions in the securities of Lexeo Therapeutics, Inc. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publicly avai |
|
| March 24, 2025 |
Employment Agreement, dated December 18, 2024, by and between the Company and Kyle Rasbach Exhibit 10.24 EMPLOYMENT AGREEMENT for KYLE RASBACH This Employment Agreement (the “Agreement”) is made between Lexeo Therapeutics, Inc. (the “Company”) and Kyle Rasbach (the “Executive”) (collectively, the “Parties”). Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment s |
|
| March 24, 2025 |
Exhibit 10.30 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS This Thir |
|
| March 24, 2025 |
Exhibit 10.27 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. RESEARCH AGREEMENT This Agreement is made by and between Lexeo Therapeutics, Inc. (“Company”) with offices at 345 Park Avenue South, Sixth Floor, New York, NY 10010, |
|
| March 24, 2025 |
Exhibit 99.1 Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerica |
|
| March 24, 2025 |
Exhibit 10.28 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS This Sec |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 24, 2025 |
Exhibit 10.29 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS This Sec |
|
| March 24, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Lexeo Therapeutics, Inc. |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-41855 LEXEO THERAPEU |
|
| March 24, 2025 |
As filed with the Securities and Exchange Commission on March 24, 2025 As filed with the Securities and Exchange Commission on March 24, 2025 Registration No. |
|
| March 24, 2025 |
Exhibit 10.32 LEXEO THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT March 24, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuan |
|
| March 24, 2025 |
Up to $75,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-283781 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 19, 2024) Up to $75,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with Leerink Partners LLC, or Leerink Partners, relating to shares of our common stock, $0.0001 par value per share, or our common stock, offered by this pros |
|
| March 24, 2025 |
Exhibit 10.31 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FOURTH AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS This Fou |
|
| March 24, 2025 |
Power of Attorney (included on the signature page hereto) As filed with the Securities and Exchange Commission on March 24, 2025 Registration No. |
|
| February 14, 2025 |
EX-1 2 ex1.htm EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in |
|
| January 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 13, 2025 |
Lexeo Therapeutics Corporate Overview January 13, 2025 Lexeo Therapeutics Corporate Overview January 13, 2025 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo’s expectations and plans regarding its current product candidates and programs, including statements regarding the timing, progress and results of preclinical and clinical trials of Lexeo’s gene therapy product candidates, the anticipated benefits of its current product candidates, the timing and likelihood of regulatory approval, and expected cash runway. |
|
| December 19, 2024 |
Lexeo Therapeutics Appoints Kyle Rasback as Chief Financial Officer Exhibit 99.1 Lexeo Therapeutics Appoints Kyle Rasback as Chief Financial Officer NEW YORK – December 19, 2024 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Dr. Kyle Rasbach has been appointed Chief |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 17, 2024 |
Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, New York 10010 Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, New York 10010 December 17, 2024 VIA EDGAR U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-283781 Acceleration Request Requested Date: December 19, 2024 Requested |
|
| December 13, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Lexeo Therapeutics, Inc. |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 Table of Contents As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| December 13, 2024 |
EX-4.3 Exhibit 4.3 LEXEO THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establis |
|
| December 2, 2024 |
As filed with the Securities and Exchange Commission on December 2, 2024 Table of Contents As filed with the Securities and Exchange Commission on December 2, 2024 Registration No. |
|
| November 14, 2024 |
LXEO / Lexeo Therapeutics, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 eventidelexeo-13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Lexeo Therapeutics, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.0001 par value per share (Title of Class of Securities) 52886X107 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing |
|
| November 14, 2024 |
LXEO / Lexeo Therapeutics, Inc. / Longitude Capital Partners IV, LLC - SC 13G/A Passive Investment SC 13G/A 1 d832706dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 52886X107 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) C |
|
| November 14, 2024 |
LXEO / Lexeo Therapeutics, Inc. / Lundbeckfond Invest A/S - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lexeo Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 52886X107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 13, 2024 |
Exhibit 99.1 Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for t |
|
| November 13, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on F |
|
| November 13, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on F |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41855 Lexeo Therapeutics, Inc. |
|
| November 13, 2024 |
Exhibit 99.1 Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for t |
|
| November 12, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| November 12, 2024 |
SC 13G 1 p24-3090sc13g.htm LEXEO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 52886X107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Ch |
|
| October 30, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on F |
|
| October 30, 2024 |
Interim Phase 1/2 Clinical Data of LX1001 for the Treatment of APOE4-associated Alzheimer’s Disease October 30, 2024 1 Exhibit 99. |
|
| October 30, 2024 |
Corporate Presentation, dated October 30, 2024 Interim Phase 1/2 Clinical Data of LX1001 for the Treatment of APOE4-associated Alzheimer’s Disease October 30, 2024 1 Exhibit 99. |
|
| October 30, 2024 |
Exhibit 99.1 Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau bi |
|
| October 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 30, 2024 |
Press Release, dated October 30, 2024 Exhibit 99.1 Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau bi |
|
| October 9, 2024 |
Lexeo Therapeutics Corporate Overview October 2024 Exhibit 99.1 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo’s expectations and plans regarding its current product candidates and programs, including statements regarding the timing, progress and results |
|
| October 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 09, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 9, 2024 |
Corporate Presentation, dated October 9, 2024 Lexeo Therapeutics Corporate Overview October 2024 Exhibit 99.1 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo’s expectations and plans regarding its current product candidates and programs, including statements regarding the timing, progress and results |
|
| October 9, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| August 12, 2024 |
Employment Agreement, dated April 10, 2024, by and between the Company and Jose Manuel Otero. Exhibit 10.2 EMPLOYMENT AGREEMENT for JOSE MANUEL OTERO, PH.D. This Employment Agreement (the “Agreement”) is made between Lexeo Therapeutics, Inc. (the “Company”) and Jose Manuel Otero, Ph.D. (the “Executive”) (collectively, the “Parties”). Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in retur |
|
| August 12, 2024 |
Third License Agreement, dated April 21, 2024, by and between Cornell University and the Company. Exhibit 10.3 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version THIRD LICENSE AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND CORNELL UNIVERSITY FOR DOCKET NO. D-9332, D-10224, D-11139 CTL CONTRACT NO. [***] 1 TABL |
|
| August 12, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| August 12, 2024 |
Exhibit 10.1 LEXEO THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel to ensure the Company’s success and accomplish the Company’s goals; (b) to incentivize Employees, Directors and Independent Contractors with long-term equity-based compensation to align their interests with the Company’s stoc |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41855 Lexeo Therapeutics, Inc. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 12, 2024 |
Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recent |
|
| August 9, 2024 |
LXEO / Lexeo Therapeutics, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lexeo Therapeutics, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.0001 par value per share (Title of Class of Securities) 52886X107 (CUSIP Number) July 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| August 9, 2024 |
EX-1 2 ex1.htm EX-1 EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agr |
|
| July 15, 2024 |
Corporate Presentation, dated July 15, 2024 Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy July 15 2024 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo’s expectations and plans regarding its current product candidates and programs, including statements regarding the anticipated benefits of LX2006 for the treatment of Friedreich Ataxia Cardiomyopathy and the timing for receipt and announcement of data from its clinical trials. |
|
| July 15, 2024 |
Exhibit 99.1 Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of participants with elevated LVMI at baseline Sustained |
|
| July 15, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 15, 2024 |
Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy July 15, 2024 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo’s expectations and plans regarding its current product candidates and programs, including statements regarding the anticipated benefits of LX2006 for the treatment of Friedreich Ataxia Cardiomyopathy and the timing for receipt and announcement of data from its clinical trials. |
|
| July 15, 2024 |
Press Release, dated July 15, 2024 Exhibit 99.1 Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of participants with elevated LVMI at baseline Sustained |
|
| July 8, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| July 8, 2024 |
Exhibit 99.1 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors NEW YORK – July 8, 2024 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Va |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 8, 2024 |
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors Exhibit 99.1 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors NEW YORK – July 8, 2024 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Va |
|
| June 28, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 28, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41855 Lexeo Therapeutics, Inc. |
|
| May 9, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| May 9, 2024 |
Exhibit 99.1 Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| April 22, 2024 |
EX-99.1 2 lxeo-ex991.htm EX-99.1 Exhibit 99.1 Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to supp |
|
| April 22, 2024 |
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh. |
|
| April 22, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| April 22, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 22, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| April 16, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 16, 2024 |
6,974,248 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated April 12, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278566 6,974,248 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2024 (as supplemented from time to time, the “Prospectus”), which forms a part of our registration statement on Fo |
|
| April 16, 2024 |
Exhibit 99.1 Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy NEW YORK – April 16, 2024 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associat |
|
| April 16, 2024 |
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy NEW YORK – April 16, 2024 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. |
|
| April 12, 2024 |
6,974,248 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-278566 PROSPECTUS 6,974,248 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 6,974,248 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), by the selling stockholders identified |
|
| April 11, 2024 |
April 11, 2024 VIA EDGAR U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attn: Tamika Sheppard Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-278566 Acceleration Request Requested Date: April 12, 2024 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to R |
|
| April 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lexeo Therapeutics, Inc. |
|
| April 9, 2024 |
Power of Attorney (included in the signature page to this Registration Statement on Form S-1) Table of Contents As filed with the Securities and Exchange Commission on April 9, 2024 Registration No. |
|
| April 9, 2024 |
Employment Agreement, dated February 3, 2024, by and between the Company and Eric Adler, M.D. Exhibit 10.8 EMPLOYMENT AGREEMENT for ERIC ADLER, M.D. This Employment Agreement (the “Agreement”) is made between Lexeo Therapeutics, Inc. (the “Company”) and Eric Adler, M.D. (the “Executive”) (collectively, the “Parties”). WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such emplo |
|
| April 9, 2024 |
Employment Agreement, dated February 2, 2024, by and between the Company and Sandi See Tai, M.D. Exhibit 10.9 EMPLOYMENT AGREEMENT for SANDI SEE TAI, M.D. This Employment Agreement (the “Agreement”) is made between Lexeo Therapeutics, Inc. (the “Company”) and Sandi See Tai, M.D. (the “Executive”) (collectively, the “Parties”). WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such |
|
| April 9, 2024 |
Exhibit 10.21 Center for Technology Licensing 1155 York Avenue New York, NY 10065 P: 646.962.7045 innovation.weill.cornell.edu February 11, 2024 Jenny Robertson Chief Business and Legal Officer Lexeo Therapeutics, Inc. 345 Park Avenue South, 6th Floor New York, NY 10010 Via email: [email protected] RE: THIRD AMENDMENT to the FIRST LICENSE AGREEMENT by and between Lexeo Therapeutics, Inc. (he |
|
| March 11, 2024 |
Exhibit 99.2 Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management and Novo Holdings A/S. NEW YORK – March 11, 2024 (GLOBE |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-41855 LEXEO THERAPEU |
|
| March 11, 2024 |
As filed with the Securities and Exchange Commission on March 11, 2024 As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. |
|
| March 11, 2024 |
Form of Common Stock Purchase Agreement, dated March 11, 2024 Exhibit 10.22 COMMON STOCK PURCHASE AGREEMENT BY AND AMONG LEXEO THERAPEUTICS, INC., AND THE PURCHASERS MARCH 11, 2024 1 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Common Stock 3 2.1 Purchase and Sale 3 2.2 Closing 4 3. Representations and Warranties of the Company 4 3.1 Financial Statements 4 3.2 No Material Adverse Change 4 3.3 Organization and Good Standing 5 3.4 Capitalization |
|
| March 11, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 Lexeo Therapeutics, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy |
|
| March 11, 2024 |
Form of Registration Rights Agreement, dated March 11, 2024 Exhibit 4.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of March 11, 2024 by and among Lexeo Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Company and the Pur |
|
| March 11, 2024 |
Exhibit 14.1 LEXEO THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS EFFECTIVE November 2, 2023 I. Code of Business Conduct and Ethics Lexeo Therapeutics, Inc. (the “Company”) is committed to creating an environment where we are able to do our best work while maintaining the highest standards of business conduct and ethics. This Code of Business Conduct and Ethics (the “Code of Conduct”) refl |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 11, 2024 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following description summarizes certain important terms of the capital stock of Lexeo Therapeutics, Inc. (“us,” “our,” “we,” “Lexeo” or the “Company”) as specified in our amended and restated certificate of incorporation and our amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by the provisions |
|
| March 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Lexeo Therapeutics, Inc. |
|
| March 11, 2024 |
Exhibit 99.1 Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data from a subset of the second dose cohort of SUNRISE-FA, a Phase 1/2 clinical trial |
|
| February 14, 2024 |
US52886X1072 / LEXEO THERAPEUTICS INC / Omega Fund VI, L.P. - SC 13G Passive Investment SC 13G 1 d791884dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. ) Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 52886X10 |
|
| February 14, 2024 |
EX-99.2 3 d791884dex992.htm EX-99.2 Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person’s true and lawful attorney-in-fact, to: (1) execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments thereto (collectively, the |
|
| February 14, 2024 |
US52886X1072 / LEXEO THERAPEUTICS INC / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243573d18sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares” |
|
| February 14, 2024 |
SC 13G 1 p24-0680sc13g.htm LEXEO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 52886X107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| February 14, 2024 |
US52886X1072 / LEXEO THERAPEUTICS INC / Lundbeckfond Invest A/S - SC 13G Passive Investment SC 13G 1 tm245429d32sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lexeo Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 52886X107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2024 |
EX-99.1 2 d791884dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned, pursuant to Rule 13d-1(k)(1) under the Act, hereby agrees and acknowledges that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the Common Stock and the information required by this Schedule 13G, to which t |
|
| February 13, 2024 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the |
|
| February 13, 2024 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 52886X107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2024 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 5, 2024 |
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments NEW YORK – February 5, 2024 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. |
|
| December 18, 2023 |
Exhibit 99.1 Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) NEW YORK – December 18, 2023 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular disease |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 15, 2023 |
LXEO / Lexeo Therapeutics Inc. / Novo Holdings A/S - SC 13G/A Passive Investment SC 13G/A 1 d67519dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 52886X107 (CUSIP Number) December 11, 2023 (Date of Event which Requires Filing of this Statement) Ch |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41855 Lexeo Therapeutics, Inc. |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 Lexeo Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41855 85-4012572 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 11, 2023 |
Exhibit 99.1 Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer’s disease Received clearance of LX2006 Clinical Trial Application (CTA) in Canada for the treatment of FA cardiomyopathy; activated first clinical trial site outside of the United |
|
| December 11, 2023 |
LXEO / Lexeo Therapeutics Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 sc13g-lexeo.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Lexeo Therapeutics, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.0001 par value per share (Title of Class of Securities) 52886X107 (CUSIP Number) November 30, 2023 (Date of Event which Requires Filing of this Sta |
|
| November 24, 2023 |
LXEO / Lexeo Therapeutics Inc. / Novo Holdings A/S - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 52886X107 (CUSIP Number) November 15, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| November 17, 2023 |
LXEO / Lexeo Therapeutics Inc. / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Lexeo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 52886X107 |
|
| November 17, 2023 |
EX-99.1 2 tm2331049d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Lexeo Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934 |
|
| November 7, 2023 |
As filed with the Securities and Exchange Commission on November 7, 2023 As filed with the Securities and Exchange Commission on November 7, 2023 Registration No. |
|
| November 7, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) LEXEO THERAPEUTICS, INC. |
|
| November 7, 2023 |
Amended and Restated Bylaws of the Registrant (as amended and currently in effect) Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LEXEO THERAPEUTICS, INC. (A DELAWARE CORPORATION) November 7, 2023 LEXEO THERAPEUTICS, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808 or in such other location as the Board |
|
| November 7, 2023 |
Exhibit 3.1 LEXEO THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Lexeo Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”): DOES HEREBY CERTIFY: FIRST: That the name of this corporation is Lexeo Therapeutics, Inc., and that this corporation was o |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Lexeo Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41855 85-4012572 (State or other jurisdiction of incorporation) (Commissi |
|
| November 6, 2023 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-274777 PROSPECTUS 9,090,910 Shares Common Stock This is an initial public offering of shares of common stock of Lexeo Therapeutics, Inc. We are offering 9,090,910 shares of our common stock. The initial public offering price is $11.00 per share. Prior to this offering, there has been no public market for our common stock. Our |
|
| November 3, 2023 |
FWP Issuer Free Writing Prospectus dated November 2, 2023 Filed Pursuant to Rule 433 Relating to Preliminary Prospectus dated November 1, 2023 Registration Statement No. |
|
| November 1, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 1, 2023 Registration No. |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Lexeo Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4012572 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No |
|
| November 1, 2023 |
Eric Blanchard +1 212 479 6565 [email protected] November 1, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tim Buchmiller Jason Drory Eric Atallah Lynn Dicker Re: Lexeo Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed October 30, 2023 File No. 333-274777 Ladies and Gentlemen: On behalf of |
|
| October 31, 2023 |
* * * [Signature Page Follows] October 31, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Attention: Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-274777 Dear Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act” |
|
| October 31, 2023 |
Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, New York 10010 Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, New York 10010 October 31, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller, Jason Drory, Eric Atallah and Lynn Dicker Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333- |
|
| October 30, 2023 |
Form of Common Stock Certificate of the Registrant Exhibit 4.2 INCORPORATED UNDER THE CUSIP 52886X 10 7 LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: COUNTERSIGNED is the record holder ofAND EQUINITI FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF (BROOKLYN, LEXEO THERAPEUTICS, INC. TRUST transferable on the books of the Corporation in person or by duly au |
|
| October 30, 2023 |
As filed with the Securities and Exchange Commission on October 30, 2023 Table of Contents As filed with the Securities and Exchange Commission on October 30, 2023 Registration No. |
|
| October 30, 2023 |
2023 Employee Stock Purchase Plan Exhibit 10.3 LEXEO THERAPEUTICS, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 13, 2023 APPROVED BY THE STOCKHOLDERS: OCTOBER 13, 2023 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Compan |
|
| October 30, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEXEO THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Lexeo Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), was originally incorporated p |
|
| October 30, 2023 |
Form of Underwriting Agreement Exhibit 1.1 LEXEO THERAPEUTICS, INC. [•] Shares of Common Stock Underwriting Agreement , 2023 J.P. Morgan Securities LLC Leerink Partners LLC Stifel, Nicolaus & Company, Incorporated RBC Capital Markets, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Leerink Partners LLC 1301 Avenue |
|
| October 30, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.3 LEXEO THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Lexeo Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”): DOES HEREBY CERTIFY: FIRST: That the name of this corporation is Lexeo Therapeutics, Inc., and that this corporation was o |
|
| October 30, 2023 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF LEXEO THERAPEUTICS, INC. (A DELAWARE CORPORATION) LEXEO THERAPEUTICS, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808 or in such other location as the Board of Directors of t |
|
| October 30, 2023 |
Exhibit 10.2 LEXEO THERAPEUTICS, INC. 2023 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 13, 2023 APPROVED BY THE STOCKHOLDERS: OCTOBER 13, 2023 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMENTS UPON CHANGES IN |
|
| October 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 Lexeo Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(4) Fees to Be Paid Equity Common Stock, par value $0.0001 per share 457(o) |
|
| October 5, 2023 |
Eric Blanchard T: (212) 479-6565 [email protected] Via EDGAR *FOIA Confidential Treatment Request* Confidential Treatment Requested by Lexeo Therapeutics, Inc. In Connection with Registration Statement on Form S-1 (File No. 377-05985) October 5, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attenti |
|
| September 29, 2023 |
Exhibit 10.19 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 395 Pine Tree Road, Suite 310 Ithaca, New York 14850 p. 607-254-4698 f. 607-254-5454 www.ctl.cornell.edu July 1, 2022 [***] RE: 1st AMENDMENT to the FIRST LICENSE AGR |
|
| September 29, 2023 |
Exhibit 10.1 LEXEO THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel to ensure the Company’s success and accomplish the Company’s goals; (b) to incentivize Employees, Directors and Independent Contractors with long-term equity-based compensation to align their interests with the Company’s stoc |
|
| September 29, 2023 |
Exhibit 10.10 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version STOCK PURCHASE AGREEMENT BY AND AMONG LEXEO THERAPEUTICS, INC., STELIOS THERAPEUTICS, INC., THE STOCKHOLDERS, AND STOCKHOLDERS’ REPRESENTATIVE Dated |
|
| September 29, 2023 |
First License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| September 29, 2023 |
Exhibit 10.7 EMPLOYMENT AGREEMENT for PAUL MCCORMAC This Employment Agreement (the “Agreement”) is made between Lexeo Therapeutics, Inc. (the “Company”) and Paul McCormac (the “Executive”) (collectively, the “Parties”). WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment |
|
| September 29, 2023 |
Exhibit 10.22 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Copy LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) is entered into on the Closing Date (as defined below) (the “Effective Date”) between ADVERUM |
|
| September 29, 2023 |
Consulting Agreement, dated July 16, 2021, between LEXEO Therapeutics, LLC and Eric Adler, M.D. Exhibit 10.9 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is made by and between Dr. Eric Adler (“Consultant”) and LEXEO Therapeutics, Inc. (the “Company”) (each a “P |
|
| September 29, 2023 |
Second License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| September 29, 2023 |
Form of Indemnification Agreement with Executive Officers and Directors Exhibit 10.4 LEXEO THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [], 20[], and is between Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directo |
|
| September 29, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEXEO THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Lexeo Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), was originally incorporated p |
|
| September 29, 2023 |
Exhibit 10.6 EMPLOYMENT AGREEMENT for JENNY R. ROBERTSON This Employment Agreement (the “Agreement”) is made between Lexeo Therapeutics, Inc. (the “Company”) and Jenny R. Robertson (the “Executive”) (collectively, the “Parties”). WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such e |
|
| September 29, 2023 |
As filed with the Securities and Exchange Commission on September 29, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 29, 2023 Registration No. |
|
| September 29, 2023 |
Exhibit 10.11 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Copy LICENSE AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR [***] TABLE OF CONTENTS Page RECITALS 1 Article 1. |
|
| September 29, 2023 |
Bylaws of the Registrant (currently in effect) Exhibit 3.2 BYLAWS OF LEXEO THERAPEUTICS, INC. ARTICLE I ARTICLE I Meetings of Stockholders Section 1.1. Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to time. Any |
|
| September 29, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 Lexeo Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Fees to Be Paid Equity Common Stock, par value $0.0001 per share 457(o) — |
|
| September 29, 2023 |
Exhibit 10.8 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEXEO THERAPEUTICS, LLC CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”), made effective on this 9th day of October, 2020 (“Effective Date”) is entered i |
|
| September 29, 2023 |
Exhibit 10.21 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION RESEARCH COLLABORATION AGREEMENT This Research Collaboration Agreement (this “Agreement”), effective as of February 3, 2021 (the “Effective Date”), is |
|
| September 29, 2023 |
Exhibit 10.18 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 395 Pine Tree Road, Suite 310 Ithaca, New York 14850 p. 607-254-4698 f. 607-254-5454 www.ctl.cornell.edu January 13, 2022 [***] RE: AMENDMENT #1 to the SECOND LICENSE A |
|
| September 29, 2023 |
Exhibit 10.5 EMPLOYMENT AGREEMENT for R. NOLAN TOWNSEND This Employment Agreement (the “Agreement”) is made between Lexeo Therapeutics, Inc. (the “Company”) and R. Nolan Townsend (the “Executive”) (collectively, the “Parties”). WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such emp |
|
| September 29, 2023 |
Exhibit 10.12 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT BETWEEN ARVC THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR [***] TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS 3 ARTICLE 2. G |
|
| September 29, 2023 |
Exhibit 10.14 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version RESEARCH AGREEMENT This Agreement is made by and between Lexeo Therapeutics, Inc. (“Company”) with offices at 430 East 29th Street, 14th Floor, New Yo |
|
| September 29, 2023 |
Exhibit 10.15 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version RESEARCH AGREEMENT This Agreement is made by and between Lexeo Therapeutics, Inc. (“Company”) with offices at 430 East 29th Street, 14th Floor, New |
|
| September 29, 2023 |
Exhibit 10.20 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 395 Pine Tree Road, Suite 310 Ithaca, New York 14850 p. 607-254-4698 f. 607-254-5454 www.ctl.cornell.edu September 28, 2022 [***] RE: 2nd AMENDMENT to the FIRST LICENSE |
|
| September 29, 2023 |
Exhibit 4.1 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of August 10, 2021, by and among Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, certain of the Inv |
|
| September 29, 2023 |
Exhibit 10.13 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT This agreement (“Agreement”) is entered into as of the date of last signature below (the “Effective Date”) by and between STELIOS THERAPEUTICS, INC., |
|
| September 18, 2023 |
Exhibit 10.14 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version RESEARCH AGREEMENT This Agreement is made by and between Lexeo Therapeutics, Inc. (“Company”) with offices at 430 East 29th Street, 14th Floor, New Yo |
|
| September 18, 2023 |
Exhibit 10.15 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version RESEARCH AGREEMENT This Agreement is made by and between Lexeo Therapeutics, Inc. (“Company”) with offices at 430 East 29th Street, 14th Floor, New |
|
| September 18, 2023 |
Exhibit 10.9 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is made by and between Dr. Eric Adler (“Consultant”) and LEXEO Therapeutics, Inc. (the “Company”) (each a “P |
|
| September 18, 2023 |
Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: +1 212 479 6000 f: +1 212 479 6275 cooley.com Eric Blanchard +1 212 479 6565 [email protected] September 18, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tim Buchmiller Jason Drory Eric Atallah Lynn Dicker Re: Lexeo Therapeutics, Inc. Amendment No. 3 to Draft Registration Statement on Form S-1 Submitted August 16, 2023 CIK No. 0001907108 Ladies and Gentlemen: On |
|
| September 18, 2023 |
Exhibit 10.22 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Copy LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) is entered into on the Closing Date (as defined below) (the “Effective Date”) between ADVERUM |
|
| September 18, 2023 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.1 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of August 10, 2021, by and among Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, certain of the Inv |
|
| September 18, 2023 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 18, 2023. |
|
| September 18, 2023 |
LEXEO THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN Exhibit 10.1 LEXEO THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel to ensure the Company’s success and accomplish the Company’s goals; (b) to incentivize Employees, Directors and Independent Contractors with long-term equity-based compensation to align their interests with the Company’s stoc |
|
| September 18, 2023 |
Exhibit 10.10 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version STOCK PURCHASE AGREEMENT BY AND AMONG LEXEO THERAPEUTICS, INC., STELIOS THERAPEUTICS, INC., THE STOCKHOLDERS, AND STOCKHOLDERS’ REPRESENTATIVE Dated |
|
| August 16, 2023 |
Exhibit 10.19 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 395 Pine Tree Road, Suite 310 Ithaca, New York 14850 p. 607-254-4698 f. 607-254-5454 www.ctl.cornell.edu July 1, 2022 [***] RE: 1st AMENDMENT to the FIRST LICENSE AGR |
|
| August 16, 2023 |
Exhibit 10.12 LICENSE AGREEMENT This agreement (“Agreement”) is entered into by and between ARVC Therapeutics, Inc. a Delaware corporation having an address at 1396 Rubenstein Ave, Cardiff by the Sea, CA 92007 (“LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5 |
|
| August 16, 2023 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 15, 2023. |
|
| August 16, 2023 |
Exhibit 10.20 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 395 Pine Tree Road, Suite 310 Ithaca, New York 14850 p. 607-254-4698 f. 607-254-5454 www.ctl.cornell.edu September 28, 2022 [***] RE: 2nd AMENDMENT to the FIRST LICENSE |
|
| August 16, 2023 |
RESEARCH COLLABORATION AGREEMENT Exhibit 10.21 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION RESEARCH COLLABORATION AGREEMENT This Research Collaboration Agreement (this “Agreement”), effective as of February 3, 2021 (the “Effective Date”), is |
|
| August 16, 2023 |
Exhibit 10.18 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.. 395 Pine Tree Road, Suite 310 Ithaca, New York 14850 p. 607-254-4698 f. 607-254-5454 www.ctl.cornell.edu January 13, 2022 [***] RE: AMENDMENT #1 to the SECOND LICENSE |
|
| August 16, 2023 |
Exhibit 10.13 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT This agreement (“Agreement”) is entered into as of the date of last signature below (the “Effective Date”) by and between STELIOS THERAPEUTICS, INC., |
|
| August 16, 2023 |
LICENSE AGREEMENT LEXEO THERAPEUTICS, INC. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Exhibit 10.11 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Copy LICENSE AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR [***] TABLE OF CONTENTS Page RECITALS 1 Article 1. |
|
| August 16, 2023 |
LEXEO THERAPEUTICS, LLC CONSULTING AGREEMENT Exhibit 10.8 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEXEO THERAPEUTICS, LLC CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”), made effective on this 9th day of October, 2020 (“Effective Date”) is entered i |
|
| August 15, 2023 |
Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: +1 212 479 6000 f: +1 212 479 6275 cooley.com Eric Blanchard +1 212 479 6565 [email protected] August 15, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tim Buchmiller Jason Drory Eric Atallah Lynn Dicker Re: Lexeo Therapeutics, Inc. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted May 17, 2023 CIK No. 0001907108 Ladies and Gentlemen: On behal |
|
| May 17, 2023 |
Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 479-6000 f: (212) 479-6275 cooley.com Eric Blanchard +1 212 479 6565 [email protected] May 17, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tim Buchmiller Jason Drory Eric Atallah Lynn Dicker Re: Lexeo Therapeutics, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted May 5, 2022 CIK No. 0001907108 Ladies and Gentlemen: On behalf of |
|
| May 17, 2023 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 17, 2023. |
|
| May 5, 2022 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 5, 2022. |
|
| May 5, 2022 |
BYLAWS LEXEO THERAPEUTICS, INC. ARTICLE I ARTICLE I Meetings of Stockholders EX-3.2 Exhibit 3.2 BYLAWS OF LEXEO THERAPEUTICS, INC. ARTICLE I ARTICLE I Meetings of Stockholders Section 1.1. Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to ti |
|
| May 5, 2022 |
[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| May 5, 2022 |
Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 479-6000 f: (212) 479-6275 cooley.com Eric Blanchard +1 212 479 6565 [email protected] May 5, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Tim Buchmiller Jason Drory Eric Atallah Lynn Dicker Re: Lexeo Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted February 4, 2022 CIK No. 0001907108 Ladies and Gentlemen: On behalf of Lexeo Therapeu |
|
| May 5, 2022 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEXEO THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Lexeo Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), was originally incorpo |
|
| May 5, 2022 |
[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| February 4, 2022 |
Table of Contents As submitted to the Securities and Exchange Commission confidentially on February 4, 2022. |
